NEW YORK (GenomeWeb) – Australian molecular diagnostics manufacturer SpeeDx is developing a line of PCR-based in vitro diagnostics called PlexPCR using the firm's proprietary single-well multiplexing technologies. The initial tests are for certain sexually transmitted infections, and include one that can detect SNPs conferring antimicrobial resistance.
The firm has been "in technology development mode for five years," Colin Denver, vice president for sales and marketing at SpeeDx, told GenomeWeb in an interview.